Effect of Puran Guda and Katu tail in management of Bronchial Asthama

A Comparative study to evaluate effectiveness of Purana guda and Katu tail in management of Tamaka Shwasa(Bronchial Asthama)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/03/017937

Enrollment

Registered

2019-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

Intervention1: Purana Guda and Katu tail: Purana Guda 1tola(12gm) Katu tail 1tola (10ml) with warm water after meal two times in a day for 21 days Control Intervention1: Standard Ayurvedic Treatment:

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients having the clinical feature of Tamaka Shwasa described in Ayurvedic classics or Bronchial Asthma modern literature- 1.Shwasa teevrvega(Breathlessness). 2.Kasa (paroxysmal cough). 3.Ghurghurakam (wheezing). 4.Nidranasha (sleeplessness). 5.Shyana shwaspeeditam(breathlessness during sleep). 6.Parsve-avagrihyate(chest tightness). 7.Lalate swedate(sweating on forehead). 8.Aasino labhtesaukhyam(dyspnoea relived in sitting position. 2.Patients exhibiting either symptoms of Bronchial Asthma as following GINA criteria for diagnosis of Asthma. 3. Age â?? 18-60 years 4. Sex â?? both 5.Patients receiving standard Ayurvedic preparation for Bronchial Asthma. 6. patients with firm home address and contact no which is readily accessible during course of trial.

Exclusion criteria

Exclusion criteria: 1. Seriously ill and moribund patients. 2. Hypersensitivity to any of the herbal dravyas. 3. Concomitant ayurvedic or any other treatment for any illness. 4. Abnormal renal or hepatic functions. 5. Patients planning to conceive in near future (during course of trial). 6. Pregnant and lactating mothers. 7. Any other pre -existing illness that will require surgery during course of trial. 8. Any major psychiatric illness. 9. Patients with any other concomitant lung disorder. 10. Patients having weak digestive capacity or suffering from indigestion.

Design outcomes

Primary

Measure	Time frame
Reduction in rate of severe asthma. Day and night time symptoms of Asthma .Day and night time symptoms of Asthma Timepoint: day 0 day 7 day 14 day 21 day 28 day 35 day 42	—

Secondary

Measure	Time frame
. Reduced eosinophil in blood Reduced serum Ig E . Reduced total eosinophil count Timepoint: day 0 day 7 day 14 day 21 day 28 day 35 day 42	—

Countries

India

Contacts

Public ContactKavita Saini

Chaudhary Brham Prakash Ayurved Charak Sansthan, New Delhi

dryogeshpandey@gmail.com9013858523

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026